Bleeding complications associated with cardiopulmonary bypass.

Area of Science:

• Cardiovascular Surgery
• Hematology
• Anesthesiology

Background:

• Bleeding after cardiopulmonary bypass (CPB) presents significant management challenges due to complex hemostatic alterations.
• Transient platelet dysfunction is a common, clinically relevant issue during CPB, though excessive bleeding occurs in a minority of patients.
• Predicting hemorrhagic complications remains difficult, with prolonged CPB times being a risk factor.

Purpose of the Study:

• To review the complexities of bleeding management following CPB.
• To discuss current and emerging strategies for minimizing blood loss and transfusion requirements.
• To evaluate the role of pharmacologic agents in improving hemostasis during and after CPB.

Main Methods:

• Literature review of studies investigating bleeding after CPB.
• Analysis of factors contributing to CPB-associated hemostatic changes.
• Evaluation of autotransfusion techniques and pharmacologic interventions.

Main Results:

• Platelet dysfunction is a universal finding during CPB, but only affects bleeding in some patients.
• Aprotinin, a protease inhibitor, demonstrates potential for reducing bleeding when administered prophylactically.
• Desmopressin is indicated for treating post-CPB bleeding, not for prevention.

Conclusions:

• CPB-induced bleeding is multifactorial, involving hemostatic changes and procedural variables.
• Pharmacologic agents like aprotinin offer promising therapeutic avenues for managing CPB-related bleeding.
• Minimizing homologous blood product use is a key driver in advancing bleeding management strategies post-CPB.